基本信息
教育经历
工作经历
研究概述
发表文章

隋建华 博士

北京生命科学研究所研究员，生物制品中心主任

Jianhua Sui, Ph.D. Assistant Investigator and Director of Biologics Research Center, NIBS, Beijing，China

Phone：86--8630

Fax： 86- E-mail：suijianhua@nibs.ac.cn


教育经历：
Education
2000
中国协和医科大学中国医学科学院 血液学研究所 病理生理学博士


Ph.D. Pathophysiology, Institute of Hematology, Peking Union Medical College & Chinese Academy of Medical Sciences, China


1997
兰州大学医学院心血管内科学硕士



M.S. Cardiovascology, Lanzhou Medical School, Lanzhou University, China


1994
兰州大学医学院 临床医学学士


B.S. Clinical Medicine, Lanzhou Medical School, Lanzhou University, China


工作经历
Professional Experience
2012–
北京生命科学研究所研究员，生物制品中心主任

Assistant Investigator and Director ofBiologicsResearchCenter
National Institute of Biological Sciences,Beijing,China

2004–2011
哈佛大学 医学院 Dana-Farber癌症研究所 讲师


Instructor
Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, US

2000–2004
哈佛大学 医学院 Dana-Farber癌症研究所 博士后

Postdoctoral Fellow
Department of Cancer Immunology & AIDS, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, US



研究概述
Research Description

我们实验室/生物制品中心以重要感染性疾病，恶性肿瘤及自身免疫疾病为研究对象，将基础生物学研究与医学应用相结合，开展以治疗性抗体为主的相关研究。主要包括：1）发现和确认新型治疗性靶分子; 2）开发治疗性人源抗体; 3）发展新型抗体工程技术; 4）以抗体为主的生物大分子制备和抗体新药临床前研究及评估等。
Our laboratory and the Biologics Research Center conduct human antibody related researches at the intersection of biology and medicine. We take interdisciplinary approaches to develop innovative biologics for diseases prevention and therapy, mainly focus on infectious diseases, cancer andautoimmune diseases. Research programs include: 1) identification and validation of novel therapeutic targets; 2) development of therapeutic human monoclonal antibodies; 3) develop new antibody engineering technologies; 4) biologics production and pre-clinical validation of new antibody drugs, etc.


部分发表文章
Selected Publications
1.
Sui J*, Deming M, Rockx B, Liddington RC, Zhu QK, Baric RS, Marasco WA. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness. J Virol 2014, 88 (23), 13769-80. (* co-senior author)

2.
Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA. Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti-Influenza A Antibodies. Clin Infect Dis 2011; 52 (8):1003-1009 [Comment in Clin Infect Dis: Donis R, and Cox N. Prospecting the Influenza Hemagglutinin to Develop Universal Vaccines, Clin Infect Dis (Editorial commentary) 2011, 52: 1010-1012.]

3.
Sui J*, Hwang WC, Perez S, Wei G, Aird D, Chen L, Santelli E, Stec B, Cadwell G, Ali M, Murakami A, Yammanuru A, Han T, Cox N, Bankston LA, Donis RO, Liddington RC and Marasco WA. Structural and Functional Basis for Broad-Spectrum Neutralization of Avian and Human Influenza A Viruses. Nat Struct Mol Bio 2009, 16(3):265-73. (*co-corresponding author) [Commented in Nat Biotech, Nat Struct Mol Bio and Nat Med: ◇ Wang TT, Palese P. Universal epitopes of inflenza virus hemagglutinins? Nat Struct Mol Biol (News and Views), 2009,16 (3):233-4. ◇ Chen, GL, Subbarao K. Attacking the flu: Neutralizing antibdoies may lead to 'universal' vaccine. Nat Med (Between Bedside and Bench), 2009, 15: 1251-1252. ◇ Influenza's Achilles' heel? Nat Biotech (Research highlights), 2009, 27 (14): 348]

4.
Sui J*, Aird DR, Tamin A, Murakami A, Yan M, Yammanur, A, Jing H, Kan B, Liu, X, Zhu Q, Yuan Q, Adams GP, Bellini WJ, Xu J, Anderson LJ and Marasco WA. Broadening of Neutralization Activity to Directly Block a Dominant Antibody-Driven SARS-Coronavirus Evolution Pathway. Plos Pathogen 2008, 4(11):e**.(* co-corresponding author)

5.
Sui J. Li W, Roberts A, Matthews LJ, Murakami A, Vogel L, Wong SK, Subbarao K, Farzan M Marasco WA. Evaluation of human mab 80r for immunoprophylaxis of SARS by an animal study, epitope mapping and analysis of spike variants. J Virol 2005, 79(10):5900-5906.

6.
Sui J, Li W, Murakami A, Tamin A, Matthews LJ, Wong SK, Moore MJ, Tallrico AS, Olurinde M, Choe H, Anderson LJ, Bellini WJ, Farzan M, and Marasco WA. Potent Neutralization of SARS Coronavirus Infection by a Human Monoclonal Antibody Against the ACE2-Binding Domain of Spike Protein. Proc Natl Acad Sci USA 2004,101(8):2536-41

7.
Sui J, He Y, Jiang X, Dubel S, Han Z, Song Z. A single chain antibody obtained by cell panning of antibody phage inhibits homoaggregation of human leukemia cells. Hum Antibodies 2004;13(4):111-118

8.
Sui J, Bai J, Tallarico A, Xu C and Marasco WA. Identification of CD4 and Transferrin Receptor Antibodies by Anti-CXCR4 Antibody Guided Pathfinder Selection. Eur J Biochem 2003; 270: 4497-4506

9.
Sui J, Marasco WA. Evidence against Ebola virus sGP binding to human neutrophils by a specific receptor. Virology 2002, 303(1):9-14

10.
He W,Ren B, Mao F, Jing Z,Li Y, Liu Y, Peng B, Yan H, Qi Y, Sun Y,Guo J-T, Sui J, Wang F, and Li W. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide. PLOS Pathog, 2015,10.1371/journal.ppat.**.

11.
Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, and W. Li*. Viral entry of hepatitis B and d viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol, 2014, 88(6): 3273-84,

12.
Yan H, Peng B, Liu Y, Xu G, He W, Ren B, Jing Z, Sui J, Li W. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol 2014,88:3273-3284.

13.
Yan H, Peng B, He W, Zhong G, Qi Y, Ren B, Gao Z, Jing Z, Song M, Xu G, Sui J, Li W. Molecular determinants of hepatitis B and D virus entry restriction in mouse sodium taurocholate cotransporting polypeptide. J Virol 2013, 87:7977-7991

14.
Zhong G, Yan H, Wang H, He W, Jing Z, Qi Y, Fu L, Gao Z, Huang Y, Xu G, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J Virol 2013, 87:7176-7184.

15.
Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. 2012. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. eLife 2012, 1:e00049.

16.
DK Chang, Sui J, Geng S, Muvaffak A, Bai M, Fuhlbrigge R, Lo A, Yammanuru A, Hubbard L, Sheehan J, Campbell J, Zhu Q, Kupper T, Marasco WA. Humanization of an anti-CCR4 antibody that kills Cutaneous T Cell Lymphoma cells and abrogates suppression by T regulatory cells. Molecular Cancer Therapeutics 2012,11 (11):2451-61

17.
Xu C, Sui J, Tao H, Zhu Q, Wayne A. Marasco. Human anti-CXCR4 antibodies undergo VH replacement, exhibit functional V-Region sulfation and define CXCR4 antigenic heterogeneity. J Immunol 2007,179(4):2408-18

18.
Li W, Sui J, Huang I-Cheuh, Kuhn JH, Radoshizky S, Marasco WA, Choe H, Farzan M. The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2. Virology 2007, 367(2):367-74

19.
Hannah G, Sui J, Foellmer H, Wang T, Ledizet M, Murakami A, Noonan K, Lambeth C, Kar K, Anderson JF, Silva A, Koski R, Marasco WA, Fikrig E. Protection against West Nile virus with human single chain Fv-Fc fusion proteins that bind the viral envelop protein. J Virol 2005, 79:14606-4613

20.
Bai J, Sui J, Demirjian A, Vollmer Jr CM, Marasco WA, Callery MP. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in Vitro. Cancer Res 2005, 65(6):2344-2352

21.
Tarnovitski N, Matthews LJ, Sui J, Gershoni JM Marasco WA. Mapping a neutralizing epitope on the SARS coronavirus spike protein: computational prediction based on affinity-selected peptides. J Mol Biol 2006, 359(1):190-201

22.
Li W, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J 2005, 24: 1634-1643

23.
Hwang WC, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco WA, Liddington RC. Structural basis of neutralization by a human anti-SARS Spike protein antibody, 80R. J Biol Chem 2006, 281(45):34610-6

24.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, Somasundaran M, Sullivan JL, Luzuriaga K, Greenough TC, Choe H, Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426(6965):450-454

25.
Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011, 208(1):181-93



特邀综述
Invited Reviews

Marasco WA, Sui J (*co-corresponding author). The growth and potential of human anti-viral monoclonal antibody therapeutics.Nature Biotechnology. 2007, 25(12):1421-34. Invited review.

专著章节
Book Chapters
Sui J, Marasco WA. Immunopathogenesis and Immunotherapy of SARS. In: Chan Jane CK, Wong VCWTaam., editor. Challenges of Severe acute respiratory syndrome.HongKong: WB Saunders; 2006. p.139-160.

专利
Patents
1.
Marasco WA, Sui J. Antibodies Against SARS-CoV and Methods of Use Thereof. Patent No.US7750，123

2.
Marasco WA, Sui J, Xu C. Antibodies against CXCR4 and Methods of Use Thereof. Patent No. US**B2;EP ** B1;CA ** C）

3.
Fikrig E, Gould H, Koski RA, Ledizet M, Marasco WA, Sui J. Antibodies to West Nile Virus Polypeptides. Publication No.：WO/2005/123774. Publication date: Dec. 29, 2005.

4.
Marasco WA, Sui J, Anvir Y. Humanized Monoclonal Antibodies and Methods of Use. Publication No.：WOA3. Publication date: Apr 5, 2012.

5.
Marasco WA, Sui J, Liddington R. Conserved Hemagglutinin Epitopes, Antibodies To The Epitope And Methods Of Use. Publication No. US A1. Publication date: May 24, 2012.

6.
Marasco WA, Sui J, Zhu Q, Kupper T. Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use. Publication No.:WO A1. Publication date: Nov 7, 2013

7.
Marasco WA, Sui J. Antibodies against H5N1 and Methods of Use Thereof. Publication No.: US A1. Publication date: Jan 9, 2014.

8.
Marasco WA, Sui J. Human monoclonal anti-PD-L1 antibodies and methods of use. (Publication No.: WOA2.). Publication date:Apr 10, 2014